| Name | Shares allotted | % of global offering | % of post-IPO shares | Lock-up |
|---|---|---|---|---|
| 嘉兴鑫扬及华泰资本投资(与华泰背对背总回报掉期及华泰客户总回报掉期有关) | 7,113,600 | 21.30% | 1.80% | 6 months |
| Rank | % of international placing | % of global offering |
|---|---|---|
| 前1名 | — | — |
With an offer price of HK$12.9 and an entry threshold of HK$2,580, the IPO drew an extraordinary oversubscription ratio of 4,007.64 times, signaling intense retail demand for this 18A biotech listing. The overall hit rate was a mere 9.87%, meaning only about one in ten applications succeeded, highlighting the fierce competition. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
The tier distribution shows a stark inefficiency at the boundary: 甲尾 applicants, applying for 300,000 shares, could expect just 0.24 lots, while 乙头 subscribers with 400,000 shares saw an expected 0.6 lots—more than double the lots for only a 33% increase in shares. This indicates a disproportionately large jump in allocation probability when crossing into the B tier. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Successful applicants were predominantly male (61.3%) with an average age of 42.8, and a striking 69.7% hailed from mainland China, underscoring the strong cross-border demand for Hong Kong biotech IPOs. Hong Kong residents accounted for just 29.5% of the allotment, pointing to a heavily mainland-driven investor base. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
This page shows allotment analysis for Ab&b Bio-Tech-B (02627): one-lot hit rate, Pool A/B allotment distribution, oversubscription multiple, and grey-market and first-day performance. Data is parsed from the HKEX allotment results announcement. How allotment rates and clawback work is explained in How Hong Kong IPO Allotment Rates Work.

